Literature DB >> 18628091

Expression of glypican 3 in ovarian and extragonadal germ cell tumors.

Debra L Zynger1, Michael J Everton, Nikolay D Dimov, Pauline M Chou, Ximing J Yang.   

Abstract

Germ cell tumors (GCTs), rare malignancies that occur in a wide range of locations and display variable histologic patterns, may pose diagnostic challenges. Glypican 3 (GPC3), a membrane-bound heparan sulfate proteoglycan, has been shown to be a novel diagnostic marker in testicular GCT. However, GPC3 expression in ovarian and extragonadal GCT has not been reported. We evaluated GPC3 immunoreactivity in GCTs from 63 patients (57 children and 6 adults), including 14 ovarian and 20 extragonadal primary GCTs and 8 metastases along with 21 primary testicular GCTs for comparison. All 33 yolk sac tumors (YSTs) and both choriocarcinomas were immunoreactive for GPC3. In contrast, a minority of immature (4/10) and mature (4/35) teratomas were positive. No positivity was seen in 6 embryonal carcinomas or 5 germinomas. GPC3 is differentially expressed in ovarian and extragonadal GCTs, with expression predominantly observed in YSTs and choriocarcinoma.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18628091     DOI: 10.1309/8DN7DQRDFB4QNH3N

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  15 in total

Review 1.  The 2015 World Health Organization Classification of Tumors of the Thymus: Continuity and Changes.

Authors:  Alexander Marx; John K C Chan; Jean-Michel Coindre; Frank Detterbeck; Nicolas Girard; Nancy L Harris; Elaine S Jaffe; Michael O Kurrer; Edith M Marom; Andre L Moreira; Kiyoshi Mukai; Attilio Orazi; Philipp Ströbel
Journal:  J Thorac Oncol       Date:  2015-10       Impact factor: 15.609

2.  ZBTB16: a novel sensitive and specific biomarker for yolk sac tumor.

Authors:  Guang-Qian Xiao; Faqian Li; Pamela D Unger; Hani Katerji; Qi Yang; Loralee McMahon; David E Burstein
Journal:  Mod Pathol       Date:  2016-02-26       Impact factor: 7.842

Review 3.  The Role of Glypicans in Cancer Progression and Therapy.

Authors:  Nan Li; Madeline R Spetz; Mitchell Ho
Journal:  J Histochem Cytochem       Date:  2020-07-06       Impact factor: 2.479

4.  Downregulation of glypican-3 expression increases migration, invasion, and tumorigenicity of human ovarian cancer cells.

Authors:  Ying Liu; Dongping Zheng; Mingming Liu; Jiao Bai; Xi Zhou; Baolan Gong; Jieyu Lü; Yi Zhang; Hui Huang; Wenying Luo; Guangrong Huang
Journal:  Tumour Biol       Date:  2015-05-14

5.  Arginase-1 is a more sensitive marker than HepPar-1 and AFP in differential diagnosis of hepatocellular carcinoma from nonhepatocellular carcinoma.

Authors:  Wei Sang; Wei Zhang; Wenli Cui; Xinxia Li; Gulinar Abulajiang; Qiaoxin Li
Journal:  Tumour Biol       Date:  2015-01-11

6.  Arginase-1: a new immunohistochemical marker of hepatocytes and hepatocellular neoplasms.

Authors:  Benjamin C Yan; Can Gong; Jie Song; Thomas Krausz; Maria Tretiakova; Elizabeth Hyjek; Hikmat Al-Ahmadie; Venancio Alves; Shu-Yuan Xiao; Robert A Anders; John A Hart
Journal:  Am J Surg Pathol       Date:  2010-08       Impact factor: 6.394

7.  Expression of glypican 3 in placental site trophoblastic tumor.

Authors:  Robin J Ou-Yang; Pei Hui; Ximing J Yang; Debra L Zynger
Journal:  Diagn Pathol       Date:  2010-09-25       Impact factor: 2.644

8.  Expression of Markers of Hepatocellular Differentiation in Pancreatic Acinar Cell Neoplasms:  A Potential Diagnostic Pitfall.

Authors:  Gokce Askan; Vikram Deshpande; David S Klimstra; Volkan Adsay; Carlie Sigel; Jinru Shia; Olca Basturk
Journal:  Am J Clin Pathol       Date:  2016-07-17       Impact factor: 2.493

9.  Malignant mixed mullerian tumor: an immunohistochemical study.

Authors:  Zhanyong Bing; Theresa Pasha; Li-Ping Wang; Paul J Zhang
Journal:  Patholog Res Int       Date:  2012-07-10

10.  The diagnostic value of arginase-1 immunostaining in differentiating hepatocellular carcinoma from metastatic carcinoma and cholangiocarcinoma as compared to HepPar-1.

Authors:  Nehal A Radwan; Naglaa S Ahmed
Journal:  Diagn Pathol       Date:  2012-10-30       Impact factor: 2.644

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.